Brokerage firm Jefferies Maintains its rating on Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA). In a research note issued to the investors, the brokerage major Lowers the price-target to $69.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Jul 14, 2016.
In a different note, On Jul 14, 2016, Oppenheimer said it Maintains its rating on Teva Pharmaceutical Industries Ltd (ADR). In the research note, the firm Lowers the price-target to $77.00 per share. The shares have been rated ‘Outperform’ by the firm. Credit Suisse said it Initiates Coverage on Teva Pharmaceutical Industries Ltd (ADR), according to a research note issued on May 4, 2016. The shares have been rated ‘Neutral’ by the firm. On May 3, 2016, Morgan Stanley said it Maintains its rating on Teva Pharmaceutical Industries Ltd (ADR). In the research note, the firm Lowers the price-target to $71.00 per share. The shares have been rated ‘Overweight’ by the firm.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) shares turned negative on Mondays trading session with the shares closing down -0.11 points or -0.20% at a volume of 48,05,469. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $54.88. The peak price level was also seen at $54.88 while the days lowest was $53.83. Finally the shares closed at $54.1. The 52-week high of the shares is $72.31 while the 52-week low is $48.01. According to the latest information available, the market cap of the company is $49,447 M.
Teva Pharmaceutical Industries Ltd (ADR)(TEVA) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $4.81B. Analysts had an estimated revenue of $4.77B. Earnings per share were $1.20. Analysts had estimated an EPS of $1.17.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines which manufactures and sells generic pharmaceutical products in several dosage forms including tablets capsules injectables inhalants liquids ointments and creams and Specialty medicines which delivers solutions to patients and providers via medicines devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda Trisenox Granix Synribo Lonquex Tevagrastim/Ratiograstim Myocet Trisenox and Eporatio. Its women’s health portfolio includes ParaGard Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.